Gilead Sciences, Inc. vs Johnson & Johnson — Stock Comparison

Gilead Sciences, Inc. (GILD) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.

Q·Score Winner
Gilead Sciences, Inc.
GILD8.2/10vs 7.1/10

Gilead Sciences, Inc. scores ahead of Johnson & Johnson on Q·Score (8.2 vs 7.1 out of 10), led by Growth (7.9 vs 5.1) and Health (7.6 vs 6.5). Analyst consensus targets imply greater upside for GILD (+27.3%) than for JNJ (+10.7%).

Price Performance

Normalised to 100 at period start — shows relative performance.

Loading…
GILDJNJ

Q·Score Breakdown

8.2
Bullish
Overall
7.1
Bullish
9.6
Quality
9.3
7.6
Health
6.5
7.9
Growth
5.1
7.7
Valuation
7.3
7.8
Sentiment
6.9
GILD

High-quality business with 43% return on equity and 31% profit margins.

JNJ

High-quality business with 26% return on equity and 22% profit margins.

earnings contracting 53% year-over-year.

Analyst Consensus

Bullish
+27.3%
Target $157.57
28 analysts
Bullish
+10.7%
Target $252.87
23 analysts

Fundamentals

GILD
JNJ
16.8×
Trailing P/E
26.5×
12.8×
Forward P/E
18.0×
30.99%
Profit Margin
21.83%
79.37%
Gross Margin
68.04%
43.36%
ROE
26.42%
4.40%
Revenue Growth
9.90%
54.80%
Earnings Growth
-52.90%
0.33
Beta
0.26
2.58%
Dividend Yield
$153.7B
Market Cap
$549.8B
52-Week Range
GILD
$10437% of range$157
JNJ
$15077% of range$252

Frequently Asked Questions

GILD vs JNJ: which stock scores better overall?

Based on Q·Score, Gilead Sciences, Inc. (GILD) scores 8.2/10 versus Johnson & Johnson (JNJ) at 7.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.

Which has better revenue growth: GILD or JNJ?

Gilead Sciences, Inc. (GILD) scores higher on Growth (7.9/10 vs 5.1/10). Gilead Sciences, Inc. reports revenue growth (4.4% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Is GILD or JNJ more attractively valued?

Gilead Sciences, Inc. (GILD) scores higher on Valuation (7.7/10 vs 7.3/10). GILD trades at 12.8× P/E versus JNJ at 18.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

What do analysts say about GILD vs JNJ?

There are 28 analysts covering GILD with a consensus price target of $157.57, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Which is more profitable: GILD or JNJ?

Gilead Sciences, Inc. (GILD) scores higher on Quality (9.6/10 vs 9.3/10). Net profit margin: GILD at 31.0%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Which has stronger financial health: GILD or JNJ?

Gilead Sciences, Inc. (GILD) scores higher on Financial Health (7.6/10 vs 6.5/10). Market beta: GILD at 0.33, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

What are the market caps of GILD and JNJ?

Gilead Sciences, Inc. (GILD) has a market capitalisation of $153.7B, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Do GILD or JNJ pay dividends?

GILD pays a dividend yield of 2.58%, while JNJ does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →

Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026